CreativeOne Wealth LLC Invests $1.48 Million in Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE)

CreativeOne Wealth LLC bought a new position in Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE – Get Rating) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 25,184 shares of the company’s stock, valued at approximately $1,484,000. CreativeOne Wealth LLC owned approximately 0.64% of Invesco Dynamic Biotechnology & Genome ETF at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the stock. Adirondack Trust Co. bought a new stake in Invesco Dynamic Biotechnology & Genome ETF during the 3rd quarter worth approximately $41,000. Creative Financial Designs Inc. ADV bought a new stake in Invesco Dynamic Biotechnology & Genome ETF during the 3rd quarter worth approximately $117,000. Atria Wealth Solutions Inc. bought a new stake in Invesco Dynamic Biotechnology & Genome ETF during the 1st quarter worth approximately $221,000. Strategic Blueprint LLC bought a new stake in Invesco Dynamic Biotechnology & Genome ETF during the 2nd quarter worth approximately $291,000. Finally, Raymond James & Associates grew its position in Invesco Dynamic Biotechnology & Genome ETF by 13.3% during the 3rd quarter. Raymond James & Associates now owns 6,210 shares of the company’s stock worth $366,000 after acquiring an additional 731 shares during the last quarter.

Invesco Dynamic Biotechnology & Genome ETF Trading Up 1.9 %

Shares of PBE opened at $62.21 on Wednesday. The business’s fifty day moving average price is $65.29 and its two-hundred day moving average price is $63.49. Invesco Dynamic Biotechnology & Genome ETF has a 52 week low of $51.39 and a 52 week high of $68.50.

Invesco Dynamic Biotechnology & Genome ETF Profile

(Get Rating)

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.